Strategic Advisory Team
BP has fostered strategic advisory relationships with key visionaries, opinion and thought leaders from across pharma, the biotechnology industry, medical practice, and academic research to ensure that we are driving novel approaches for the rapid advance of innovation in the delivery of safe and cost-effective therapeutics, important diagnostics and new technologies in research, clinical and regulatory practices in the CNS.
 | Matt Veatch Head of Programs Former Strategic Operations VP, Syneos Health Former Head of Real World Data-Driven Research, Quintiles Pharma Interface, Regulatory Strategy and Pathway management, Clinical Trial and Licensing initiatives |
 | Kathleen M Metters, PhD Advisor Former Senior Vice President with oversight of Merck's global research projects Former President and CEO of Lycera |
 | Ramon Diaz-Arrastia, MD, PhD Presidential Professor of Neurology, Penn Medicine Assoc Director for Clinical Research, Center for Neurodegeneration and Repair, Penn Medicine Director of Traumatic Brain Injury Clinical Research Center, Penn Medicine TRACK-TBI Executive Committee BP’s Principal Investigator in Clinical Study of neuroinflammation |
 | Micheal Geschwind, MD, PhD Professor of Neurology, UCSF Memory and Aging Center Specialist in neurodegenerative disorders, including progressive dementias, prion disease BP’s advisor on prion disease models, biomarkers, outcomes |
 | John Kelley Chairman and Chief Executive Officer, CereScan and CereHealth Member, Forbes Technology Council Chairman, President, and Chief Executive Officer of McDATA Corporation BP and CereHealth have formed a strategic alliance to advance CereMetrix, an FDA-cleared data analytics platform, to evaluate and correlate outcome measures utilized in CNS clinical trials (including the BP clinical trial) |
 | Philip Harvey, PhD Professor of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine. Formerly professor of Psychiatry at Mt. Sinai School of Medicine and Chief Psychologist at Mt. Sinai Hospital. Developing composite clinical measure for BP’s clinical trial in neuroinflammation Further advising BP on link between depression and Alzheimer’s Disease |